Using air purifiers to help heart failure patients
Effectiveness of Indoor Air Purifiers on Heart Failure Outcomes
This study tests if using portable air purifiers can help heart failure patients in India breathe better and improve their heart function by reducing harmful air pollution.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 255 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | NYU Langone Health Academic / other |
| Locations | 3 sites (Thiruvananthapuram, Kerala and 2 other locations) |
| Trial ID | NCT05230784 on ClinicalTrials.gov |
What this trial studies
This trial investigates the impact of portable air filters on indoor air quality and the functional capacity of heart failure patients with reduced ejection fraction in India. It aims to demonstrate the efficacy, feasibility, and effectiveness of these air purifiers in reducing PM2.5 levels, which are known to contribute to cardiovascular issues. The study will compare the effects of an active air purifier against a placebo filter among eligible participants. The findings could provide insights into innovative strategies for improving both environmental and cardiovascular health.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with heart failure with reduced ejection fraction of 40% or less within the last six months.
Not a fit: Patients who are listed for a cardiac transplant, have severe pulmonary disease, or are unable to ambulate may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved health outcomes for heart failure patients by enhancing their functional capacity through better air quality.
How similar studies have performed: While the approach of using air purifiers for heart failure patients is innovative, similar studies have shown potential benefits of improving air quality on cardiovascular health.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults ≥ 18 years of age diagnosed with HF with a reduced ejection fraction of ≤ 40% within the last six months in NYHA class II-IV. Exclusion Criteria: * listed for a cardiac transplant * history of CRT device implantation in last 3 months * on oxygen therapy * with severe pulmonary disease * participants unable to ambulate
Where this trial is running
Thiruvananthapuram, Kerala and 2 other locations
- Centre for Chronic Disease Control (CCDC) — Thiruvananthapuram, Kerala, India (Recruiting)
- All India Institute of Medical Sciences (AIIMS) — Delhi, Punjab, India (Recruiting)
- Public Health Foundation of India (PHFI) — Ludhiana, Punjab, India (Recruiting)
Study contacts
- Principal investigator: Rajesh Vedanthan, MD, MPH — NYU Langone Health
- Study coordinator: Rajesh Vedanthan, MD, MPH
- Email: Rajesh.vedanthan@nyulangone.org
- Phone: 646-501-3890
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.